What diseases can pemigatinib treat?

Pemigatinib (Pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma that harbors fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements detected by an FDA-approved test. Pemetinib is also indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid tumors associated with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Before treatment, patients must select patients with locally advanced or metastatic cholangiocarcinoma based on the presence of FGFR2 fusions or rearrangements detected by FDA-approved tests. Currently, there are no FDA-approved tests to detect FGFR1 rearrangements in patients with relapsed or refractory myeloid/lymphoid tumors for selecting patients to receive pemetinib.